Trifluoro-1-hydroxyethyl-methoxypyrrolidinyl-2-trifluoromethyl-bezonitrile is a metabolite of LGD-4033 (Ligandrol).
Ligandrol was originally developed for the treatment of muscle wasting conditions such as aging, osteoporosis, muscular dystrophy and cancer. It is promoted as a selective non-steroidal anabolic agent.
It is claimed to be a substance that induces muscle (and bone) growth without the side effects associated with steroid use. However, information on the safety of LGD-4033 is scarce due to a lack of medium and long-term clinical trials - hence the medium and long-term health impacts are unknown.